Four in 10 Adults With Diabetes Report Taking a GLP-1 Receptor Agonist
By Lori Solomon HealthDay Reporter
TUESDAY, May 14, 2024 -- One in eight adults (12 percent) say they have ever taken a glucagon-like peptide-1 receptor agonist (GLP-1 RA) and 6 percent say they are currently using one, according to the results of a new KFF Health Tracking Poll, released May 10.
Alex Montero, from KFF Health, and colleagues analyzed data collected April 23 to May 1, 2024, online and by telephone, among a nationally representative sample of 1,479 U.S. adults in English and Spanish.
Survey results show that of the adults who report ever using GLP-1 RAs, 43 percent do so for diabetes, 25 percent for heart disease, and 22 percent for overweight or obesity. By race, Black and Hispanic adults report higher use than White adults (18, 13, and 10 percent, respectively). Most users say they took the drug to treat a chronic condition, including diabetes or heart disease (62 percent), while four in 10 say they took it primarily to lose weight. More than half of users (54 percent) say it was difficult to afford the cost, including 22 percent who say it was "very difficult." Even among insured adult users, 53 percent report the cost was difficult to afford.
"About eight in ten (79 percent) adults who have taken GLP-1 drugs report getting these drugs or a prescription for them from their primary care doctor or a specialist, while fewer report getting them from an online provider or website (11 percent), a medical spa or aesthetic medical center (10 percent), or from somewhere else (2 percent)," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
Ultraprocessed Foods Increase Adiposity, Cardiometabolic Risk in Children
WEDNESDAY, May 22, 2024 -- High ultraprocessed food (UPF) consumption in young children is associated with adiposity and other cardiometabolic risk factors, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.